Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
12:46pm, Thursday, 11'th Jun 2020
Investors need to pay close attention to Celldex Therapeutics (CLDX) stock based on the movements in the options market lately.
6 Stocks And Targets To Watch
12:00am, Thursday, 11'th Jun 2020
Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Ballard Power Systems Inc, Tesla Inc, Riot Blockchain Inc. Read Harry Boxer's latest article on Investing.com
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN)
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 8)
Biohaven Pharmaceutical...
Global Nivolumab Market 2020 Industry Analysis by Key Players, Product Type, Application, Regions and Forecast to 2026
11:55am, Sunday, 07'th Jun 2020
Jun 07, 2020 (CDN Newswire via Comtex) --
The dedicated research report titled Global Nivolumab Market 2020 by Manufacturers, Regions, Type and Application,...
Celldex Therapeutics, Inc. (CLDX) today announced results from the Company’s Phase 1 randomized, double-blind, placebo-controlled, dose escalation study of KIT inhibitor CDX-0159 in healthy subjects
Hedge Funds Are Dumping Celldex Therapeutics, Inc. (CLDX)
07:22pm, Thursday, 28'th May 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
03:30pm, Monday, 25'th May 2020
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex Provides Corporate Update and Reports First Quarter 2020 Results
08:01pm, Wednesday, 06'th May 2020
HAMPTON, N.J., May 06, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite.
Is Celldex Therapeutics, Inc. (CLDX) Stock Outpacing Its Medical Peers This Year?
03:30pm, Wednesday, 06'th May 2020
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex Therapeutics, Inc. (CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of A
Celldex (CLDX) Soars: Stock Adds 10% in Session
12:56pm, Friday, 24'th Apr 2020
Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CMG, CLDX among premarket gainers
01:19pm, Wednesday, 22'nd Apr 2020
SAExploration Holdings (NASDAQ:SAEX) +177% on $27M new project in Greece.B.O.S. Better Online Solutions (NASDAQ:BOSC) +56% on $1M order.The Peck Company Holdings (NASDAQ:PECK) +51% on partnership w
Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug
03:42pm, Monday, 20'th Apr 2020
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
03:15pm, Wednesday, 15'th Apr 2020
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
